ContraFect (NASDAQ:CFRX) Stock Passes Below Two Hundred Day Moving Average of $5.48

ContraFect Co. (NASDAQ:CFRX – Get Rating)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.48 and traded as low as $1.54. ContraFect shares last traded at $1.55, with a volume of 91,075 shares changing hands.

Analyst Ratings Changes

CFRX has been the subject of several recent analyst reports. Maxim Group upgraded shares of ContraFect from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Thursday, April 13th. StockNews.com downgraded shares of ContraFect from a “hold” rating to a “sell” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $180.75.

ContraFect Stock Performance

The stock has a market capitalization of $2.23 million, a P/E ratio of -0.02 and a beta of 0.44. The company’s fifty day simple moving average is $1.66 and its two-hundred day simple moving average is $5.37.

ContraFect (NASDAQ:CFRX – Get Rating) last announced its earnings results on Friday, March 31st. The biotechnology company reported ($16.14) EPS for the quarter. On average, research analysts predict that ContraFect Co. will post -15.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. bought a new position in ContraFect in the first quarter valued at approximately $41,000. Dimensional Fund Advisors LP boosted its position in ContraFect by 62.9% in the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 43,564 shares in the last quarter. State Street Corp boosted its position in ContraFect by 33.5% in the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock valued at $474,000 after buying an additional 32,563 shares in the last quarter. Virtu Financial LLC acquired a new stake in ContraFect in the third quarter valued at approximately $31,000. Finally, Two Sigma Investments LP acquired a new stake in ContraFect in the third quarter valued at approximately $39,000. 27.34% of the stock is owned by institutional investors.

ContraFect Company Profile

(Get Rating)

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.